LightNews LightNews
gmac50.bsky.social
@gmac50.bsky.social
50 followers 450 following 0 posts
Posts Replies Media Videos
Reposted
chantzy.bsky.social
I've made a Covid conscious starter pack called "Salting the Vibes" - voices on advocacy and/or science 🧬

go.bsky.app/5871Mhv
November 11, 2024 at 4:41 PM
Reposted
whimsicalmuse.bsky.social
All I want is a cottage in the Scottish Highlands, a raging snowstorm, and Agatha Christie novel, a crackling fire, a kettle on the stove, and a basket of emotional support pastries.
November 25, 2024 at 11:51 AM
Reposted
stoptheshitnado.bsky.social
Me.
November 23, 2024 at 5:34 AM
Reposted
thesicktimes.org
🧪 Here’s what’s happening this week in #LongCOVID research: bit.ly/4hB2a5b

💌 Sign up for our newsletter and get updates delivered directly to your inbox every week! thesicktimes.org/newsletter/
THE SICK TIMES: Polybio Research Foundation awarded Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) $800,000 for a new clinical trial to study the immunosuppressive drug, rapamycin. Low-dose rapamycin is an exciting drug target that has the potential to directly address some of the immune or infection-related dysfunction that many people [with Long COVID] are experiencing,” said David Putrino in a press release. Rapamycin is also being studied in a pilot trial for people with myalgic encephalomyelitis (ME). THE SICK TIMES: A new study found that during the first three years of the COVID-19 pandemic, younger people of color were more heavily impacted than white people. Researchers assessed nearly 1.4 million excess deaths during the public health emergency and compared them to the normal death rate; their data suggests Indigenous people experienced the highest rate of all-cause excess mortality and the greatest disparity. They also found that the largest increases in mortality occurred among adults ages 25 to 64 years in all race and ethnicity groups. Access to telemedicine, at-home COVID-19 tests, and rapid Paxlovid delivery to immunocompromised people reduced the severity of COVID-19 infections, a new preprint found. “The intervention was estimated to result in a reduction of $3,650 in the cost of COVID care per person,” the study’s authors wrote. “We recommend that payers and public health organizations provide COVID tests and rapid treatment to high-risk individuals, at no cost to the individuals, for as long as the virus continues to circulate.”
November 7, 2024 at 4:17 PM